TRBV6-4: A Protein with Immune and Cancer-Related Functions (G28603)

Target Name: TRBV6-4

NCBI ID: G28603

TRBV6-4

Other Name(s): TCRBV6S4 | T cell receptor beta variable 6-4 | TRBV64 | TCRBV13S5

TRBV6-4: A Protein with Immune and Cancer-Related Functions

TRBV6-4 (TcRBV6S4) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the T-cell receptor B family, which is a group of proteins that play a critical role in the immune system.

One of the unique features of TRBV6-4 is its structure. It consists of a single chain of 218 amino acids, and it has a characteristic Rossmann-fold that is present in many proteins that belong to the T-cell receptor B family. This fold is thought to be involved in the protein's ability to interact with DNA and other molecules.

TRBV6-4 is also known for its role in the development and progression of various diseases, including cancer. Studies have shown that high levels of TRBV6-4 are associated with an increased risk of cancer, and that inhibiting its activity may be a promising strategy for cancer treatment.

In addition to its potential as a cancer drug target, TRBV6-4 is also a potential biomarker for various diseases. For example, high levels of TRBV6-4 have been shown to be associated with the development of cardiovascular disease, and it may be a useful indicator of disease risk in patients with heart disease.

Another potential application of TRBV6-4 is its use as a target for small molecule inhibitors. The T-cell receptor B family is known for its ability to recognize specific DNA sequences, and this property makes it an attractive target for small molecule inhibitors. Researchers are currently working to develop small molecule inhibitors that can specifically target TRBV6-4 and inhibit its activity.

In conclusion, TRBV6-4 is a protein that has important roles in the immune system and in the development and progression of various diseases. Its unique structure and its association with cancer make it a promising target for small molecule inhibitors. Further research is needed to fully understand its potential as a drug and biomarker.

Protein Name: T Cell Receptor Beta Variable 6-4

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV6-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV6-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets